Screener / SEC EDGAR /CIK 0000914475 /10-K filed Feb 11, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Neurocrine Biosciences Inc NBIX

Compare with peers Embed
Earnings releases

Latest results release: Nov 2, 2026

8-K item 2.02, exhibit 99

What NBIX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 2, 2026 · EX-99.1

Neurocrine Biosciences Reports Third-Quarter 2026

Open on SEC

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026.

“Our third quarter performance marks another important milestone in Neurocrine’s evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in- class medicines,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “This continued growth reinforces the strength of our strategy and expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company. Looking ahead to 2027, we see meaningful opportunities for continued growth across INGREZZA, CRENESSITY ® (crinecerfont) and VYKAT ® (diazoxide choline) XR, alongside multiple important clinical milestones, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia.”

• Total revenues for the third-quarter 2026 were $1.1 billion, compared with $795 million in the prior-year period representing 41% year-over-year growth.

• INGREZZA third-quarter 2026 net product sales were $801 million, representing 17% growth year-over-year. Results reflected double-digit volume growth, with record TRx and NRx supported by strong demand and high rates of persistency.

• INGREZZA full year 2026 guidance was increased from a range of $2.825 billion to $2.875 billion up to $2.9 billion to $2.925 billion.

• CRENESSITY third-quarter 2026 net product sales were $211 million, driven by steady new patient demand and high rates of persistency with approximately 80% reimbursement for dispensed prescriptions.

• VYKAT XR third-quarter 2026 net product sales were $107 million, driven by steady and consistent patient demand and persistency.

• Announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-’1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. This follows the Q1 2026 initiation of a Phase 1 first-in-human clinical study of NBIP-’2118, a potential first-in-class CRF2 peptide agonist. Initial clinical data from both programs will inform the development of a novel co-formulated combination therapy, including the optimal ratio of the two agents. NBIP-’2118 will also be evaluated independently as a potential standalone therapy for obesity.

• Announced the initiation of a Phase 2 clinical study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-’567, an investigational M1/M4 (M1-preferring) selective muscarinic agonist being developed as an adjunctive therapy for cognitive impairment in Alzheimer’s disease.

• Announced publication of the KINECT-PRO™ Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA capsules resulted in substantial and sustained improvements in patient-reported quality of life and functionality, alongside improvements in clinician-rated tardive dyskinesia (TD) movement severity. Improvements were observed regardless of underlying psychiatric diagnosis or baseline TD movement severity, including among participants with clinician-rated mild TD movements. The manuscript appears in CNS Spectrums.

• Presented research advancing the understanding of Prader-Willi syndrome and real-world experience with VYKAT XR at the Foundation for Prader-Willi Research Symposium & Family Conference.

• Announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and most recently as a Strategic Advisor, has rejoined the Company's executive management team as Chief Medical Officer (CMO).

(unaudited, in millions, Three Months except per Ended share data) September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Total $ 1,123 $ 795 Revenues GAAP Cost of $ 27 $ 13 Revenues Non-GAAP Cost $ 20 $ 13 of Revenues GAAP Research and $ 352 $ 250 Development (R&D) Non-GAAP R&D $ 317 $ 228 GAAP Selling, General, and $ 366 $ 292 Administrati… (SG&A) Non-GAAP SG&A $ 327 $ 259 GAAP Net $ 207 $ 210 Income GAAP Earnings Per Share – $ 1.96 $ 2.04 Diluted Non-GAAP Net $ 347 $ 222 Income Non-GAAP Earnings Per $ 3.29 $ 2.17 Share – Diluted (unaudited, September 30, December 31, in millions) 2026 2025 Total Cash, Cash Equivalents, $ 790 $ 2,543 and Marketable Securities

• Third-quarter 2026 GAAP net income and earnings per share were $207 million and $1.96, respectively, compared with $210 million and $2.04, respectively, for third-quarter 2025.

• Third-quarter 2026 Non-GAAP net income and earnings per share were $347 million and $3.29, respectively, compared with $222 million and $2.17, respectively, for third-quarter 2025.

• A reconciliation of GAAP to Non-GAAP financial results can be found in Table 3 at the end of this press release.

• Third-quarter 2026 GAAP and Non-GAAP net income compared with third-quarter 2025 were primarily driven by:

◦ Third-quarter 2026 GAAP operating expenses included certain expenses associated with the acquisition of Soleno Therapeutics, Inc. (Soleno), which closed in May 2026, and are excluded from Non-GAAP operating expenses.

◦ Increased R&D expense in support of an expanded and advancing pre-clinical and clinical portfolio included investments in the osavampator Phase 3 program in major depressive disorder (MDD) and the muscarinic franchise, including the direclidine Phase 3 program as a potential treatment for adults with schizophrenia. Development milestone expense included in R&D was $10 million and $1 million, respectively, for the third quarter 2026 and 2025.

◦ Increased SG&A expense primarily reflected continued investment in our commercial organization, included the expansion of our INGREZZA and CRENESSITY sales teams in the first quarter of 2026 and for support of VYKAT XR following the acquisition of Soleno, which closed in May 2026.

◦ Third-quarter 2026 includes $52 million loss from changes in fair values of equity investments, compared with a gain of $31 million for third quarter 2025 (Non-GAAP adjustment)

• At September 30, 2026, the Company had cash, cash equivalents, and marketable securities totaling approximately $790 million.

1. INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington’s disease.

2. R&D guidance reflects the continued advancement of the Company’s pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and includes approximately $33 million of expense for development milestones related to our in-licensed product candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve.

3. Non-GAAP guidance has been adjusted to exclude estimated non-cash stock-based compensation expense of approximately $115 million in R&D and $170 million in SG&A, including approximately $58 million related to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction, and acquisition, integration and divestiture-related expenses of approximately $95 million. Non-cash stock-based compensation expense for performance-based equity awards is included in guidance once the predefined performance-based criteria for vesting is achieved or deemed probable to achieve.

4. IPR&D guidance represents completed collaboration and licensing arrangements.

5. SG&A guidance reflects expense for ongoing commercial initiatives, including the recent expansion of our sales teams in Q1 2026, supporting INGREZZA growth and the launch of CRENESSITY and VYKAT XR.

6. In connection with the acquisition of Soleno, the Company recorded approximately $2.2 billion of intellectual property related to VYKAT XR to the balance sheet, which will be amortized over an expected life of 16 years.

Neurocrine Biosciences will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Participants can access the live conference call by dialing 800-347-6865 (US) or 203-518-9757 (International) using the conference ID: NBIX. The webcast and accompanying slides can also be accessed at approximately 4:30 p.m. Eastern Time on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (* in collaboration with AbbVie )

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. VYKAT is a registered trademark of Soleno Therapeutics, Inc.

In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following Non-GAAP financial measures: Non-GAAP cost of revenues, Non-GAAP R&D expense, Non-GAAP SG&A expense, Non-GAAP other income (expense), net, Non-GAAP net income and earnings per share. When preparing the Non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these Non-GAAP financial measures exclude: non-cash stock-based compensation expense, amortization expense related to acquired intangible assets, amortization expense related to acquisition-date inventory fair value step-up, stock based compensation expense related to the acceleration of vesting of equity awards for Soleno employees, changes in fair value of equity investments, acquisition- related transaction and integration costs, gains on sales of businesses, net of transaction costs, other divestiture-related transaction costs, changes in foreign currency exchange rates and certain adjustments to income tax expense. These Non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these Non-GAAP financial measures are useful to investors because they help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these Non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&D and SG&A expenses on both a GAAP and a Non-GAAP basis. A reconciliation of these GAAP financial results to Non-GAAP financial results is included in the attached financial information.

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully commercializing CRENESSITY and VYKAT XR; our financial and operating performance, including our future revenues, expenses, or profits; our full year 2026 financial guidance; our acquisition of Soleno Therapeutics, including the prospective benefits of the acquisition, and our strategy, plans, objectives, expectations (financial or otherwise) and intentions with respect to our future financial results, growth potential and anticipated product portfolio in connection with the acquisition; our collaborative partnerships; clinical and scientific data updates for our products and product candidates, including observations regarding clinical outcomes, safety, and tolerability; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements, include but are not limited to the following: risks and uncertainties associated with Neurocrine Biosciences’ business and finances in general; risks and uncertainties associated with the commercialization of our products; risks related to our ability to realize the anticipated benefits of the acquisition of Soleno Therapeutics, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that we will not be able to integrate Soleno Therapeutics’ business successfully or that such integration may be more difficult, time-consuming or costly than expected, disruption from the acquisition, making it more difficult to conduct business as usual or maintain relationships with employees, customers, suppliers, other business partners or governmental entities, unknown or inestimable liabilities, the risk of litigation and/or regulatory actions related to the acquisition, and the degree and pace of market uptake of VYKAT XR; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law. ###

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash, cash equivalents, and marketable $ 737.9 $ 1,480.4 securities Accounts receivable 957.3 686.8 Inventory 66.1 69.0 Other current assets 246.9 286.5 Total current assets 2,008.2 2,522.7 Noncurrent inventory 177.7 — Noncurrent marketable securities 51.8 1,063.0 Right-of-use assets 437.2 455.4 Equity investments 95.0 120.8 Property and equipment, net 92.2 89.8 Intangible assets, net 2,191.0 4.7 Goodwill 500.6 6.1 Deferred tax assets 11.8 320.3 Other noncurrent assets 61.9 48.7 Total assets $ 5,627.4 $ 4,631.5 Total current liabilities 984.6 743.4 Deferred tax liabilities 105.0 — Noncurrent operating lease 392.3 415.3 liabilities Other noncurrent liabilities 266.8 219.7 Stockholders’ equity 3,878.7 3,253.1 Total liabilities and stockholders’ $ 5,627.4 $ 4,631.5 equity

GAAP gain on sale of busine… $ — $ — $ -28.6 $ — net of transa… costs Adjust… Gain on sale of busine… — — -28.6 — net of transa… costs5 Non-GA… gain on sale of busine… $ — $ — $ — $ — net of transa… costs Other Income (Expen… GAAP other (expen… $ -47.6 $ 52.8 $ 16.5 $ 57.8 income, net Adjust… Changes in fair values 52.3 -30.6 25.8 6.7 of equity invest… Acquis… transa… and — — 5.1 — integr… costs Other7 0.3 0.3 0.5 0.7 Non-GA… other $ 5.0 $ 22.5 $ 47.9 $ 65.2 income, net

2. Relates to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction.

3. Relates to amortization expense associated with recording approximately $168 million of VYKAT XR inventory fair value step-up.

4. Primarily relates to amortization of acquired intangible assets associated with the recording of approximately $2.2 billion of intellectual property related to VYKAT XR, which will be amortized over 16 years.

5. Reflects a pre-tax gain, net of transaction costs, recognized on the sale of Neurocrine Group Limited in January 2026.

7. Reflects non-cash interest expense related to the Company's credit facility, legacy campus facility costs, net of sublease income, and other immaterial costs that management does not consider indicative of the Company's ongoing operating performance.

8. Estimated income tax effect of Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance. In addition, Non-GAAP tax expense may also be affected by certain non-recurring, non-operating, or discrete tax items.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
               Neurocrine Biosciences Reports Third-Quarter 2026                
                               Financial Results                                
                                                                                
    Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion    
                                                                                
                                    INGREZZA                                    
                                                                                
    ® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion    
                                                                                
   SAN DIEGO                                                                    
                                                                                
, Nov. 2, 2026
                                                                                
  –                                                                             
                                                                                
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial
results for the third quarter ended September 30, 2026.

“Our third quarter performance marks another important milestone in Neurocrine’s
evolution, with net product sales exceeding $1 billion for the first time,
driven by strong underlying demand across our diversified portfolio of first-in-
class medicines,” said Kyle W. Gano, Ph.D., Chief Executive Officer of
Neurocrine Biosciences. “This continued growth reinforces the strength of our
strategy and expands our capacity to invest in innovation, advance our pipeline
and build an enduring biopharmaceutical company. Looking ahead to 2027, we see
meaningful opportunities for continued growth across INGREZZA, CRENESSITY ®
(crinecerfont) and VYKAT ® (diazoxide choline) XR, alongside multiple important
clinical milestones, including Phase 3 readouts for osavampator in major
depressive disorder and direclidine in schizophrenia.”
                                                                                
  Total Revenue Highlights                                                      
                                                                                
                                                                                
  (unaudited, in                                                                
  millions, except per    Three Months Ended                                    
  share data)             September 30,                                         
  Revenues:               2026                         2025         YoY Growth  
 ────────────────────────────────────────────────────────────────────────────── 
  INGREZZA Net Product    $                     801    $     687    17%         
  Sales                                                                         
  CRENESSITY Net                                211           98    115%        
  Product Sales                                                                 
  VYKAT XR Net Product                          107            —    NM          
  Sales                                                                         
  Other Revenues                                  4           10    NM          
  Total Revenues          $                   1,123    $     795    41%         
                                                                                
• Total revenues for the third-quarter 2026 were $1.1 billion, compared with
$795 million in the prior-year period representing 41% year-over-year growth.

• INGREZZA third-quarter 2026 net product sales were $801 million, representing
17% growth year-over-year. Results reflected double-digit volume growth, with
record TRx and NRx supported by strong demand and high rates of persistency.

• INGREZZA full year 2026 guidance was increased from a range of $2.825 billion
to $2.875 billion up to $2.9 billion to $2.925 billion.

• CRENESSITY third-quarter 2026 net product sales were $211 million, driven by
steady new patient demand and high rates of persistency with approximately 80%
reimbursement for dispensed prescriptions.

• VYKAT XR third-quarter 2026 net product sales were $107 million, driven by
steady and consistent patient demand and persistency.
                                                                                
  Recent Clinical and Corporate Developments                                    
                                                                                
• Announced the initiation of a Phase 1 first-in-human clinical study evaluating
the safety and tolerability of NBIP-’1968, an investigational GLP-1/GIP/glucagon
receptor triple agonist being developed as a therapy for obesity. This follows
the Q1 2026 initiation of a Phase 1 first-in-human clinical study of NBIP-’2118,
a potential first-in-class CRF2 peptide agonist. Initial clinical data from both
programs will inform the development of a novel co-formulated combination
therapy, including the optimal ratio of the two agents. NBIP-’2118 will also be
evaluated independently as a potential standalone therapy for obesity.

• Announced the initiation of a Phase 2 clinical study evaluating the efficacy,
safety, tolerability and pharmacokinetics of NBI-’567, an investigational M1/M4
(M1-preferring) selective muscarinic agonist being developed as an adjunctive
therapy for cognitive impairment in Alzheimer’s disease.

• Announced publication of the KINECT-PRO™ Phase 4 open-label study results
demonstrating that treatment with once-daily INGREZZA capsules resulted in
substantial and sustained improvements in patient-reported quality of life and
functionality, alongside improvements in clinician-rated tardive dyskinesia (TD)
movement severity. Improvements were observed regardless of underlying
psychiatric diagnosis or baseline TD movement severity, including among
participants with clinician-rated mild TD movements. The manuscript appears in
CNS Spectrums.

• Presented research advancing the understanding of Prader-Willi syndrome and
real-world experience with VYKAT XR at the Foundation for Prader-Willi Research
Symposium & Family Conference.

• Announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's
Chief Medical Officer and most recently as a Strategic Advisor, has rejoined the
Company's executive management team as Chief Medical Officer (CMO).

• Company to host R&D Day in New York on December 15, 2026.
                                                                                
   Third-Quarter 2026 Financial Results                                         
                                                                                
                                                                                
                 (unaudited, in                                                 
                 millions,       Three Months                                   
                 except per      Ended                                          
                 share data)     September 30,     2026                   2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Total                          $                1,123    $               795  
  Revenues                                                                      
  GAAP Cost of                   $                   27    $                13  
  Revenues                                                                      
  Non-GAAP Cost                  $                   20    $                13  
  of Revenues                                                                   
  GAAP Research                                                                 
  and                            $                  352    $               250  
  Development                                                                   
  (R&D)                                                                         
  Non-GAAP R&D                   $                  317    $               228  
  GAAP Selling,                                                                 
  General, and                   $                  366    $               292  
  Administrati…                                                                 
  (SG&A)                                                                        
  Non-GAAP SG&A                  $                  327    $               259  
  GAAP Net                       $                  207    $               210  
  Income                                                                        
  GAAP Earnings                                                                 
  Per Share –                    $                 1.96    $              2.04  
  Diluted                                                                       
  Non-GAAP Net                   $                  347    $               222  
  Income                                                                        
  Non-GAAP                                                                      
  Earnings Per                   $                 3.29    $              2.17  
  Share –                                                                       
  Diluted                                                                       
  (unaudited,                    September 30,             December 31,         
  in millions)                   2026                      2025                 
  Total Cash,                                                                   
  Cash                                                                          
  Equivalents,                   $                  790    $             2,543  
  and                                                                           
  Marketable                                                                    
  Securities                                                                    
                                                                                
• Third-quarter 2026 GAAP net income and earnings per share were $207 million
and $1.96, respectively, compared with $210 million and $2.04, respectively, for
third-quarter 2025.

• Third-quarter 2026 Non-GAAP net income and earnings per share were $347
million and $3.29, respectively, compared with $222 million and $2.17,
respectively, for third-quarter 2025.

• A reconciliation of GAAP to Non-GAAP financial results can be found in Table 3
at the end of this press release.

• Third-quarter 2026 GAAP and Non-GAAP net income compared with third-quarter
2025 were primarily driven by:

◦ Higher net product sales of $329 million.

◦ Third-quarter 2026 GAAP operating expenses included certain expenses
associated with the acquisition of Soleno Therapeutics, Inc. (Soleno), which
closed in May 2026, and are excluded from Non-GAAP operating expenses.

◦ Increased R&D expense in support of an expanded and advancing pre-clinical and
clinical portfolio included investments in the osavampator Phase 3 program in
major depressive disorder (MDD) and the muscarinic franchise, including the
direclidine Phase 3 program as a potential treatment for adults with
schizophrenia. Development milestone expense included in R&D was $10 million and
$1 million, respectively, for the third quarter 2026 and 2025.

◦ Increased SG&A expense primarily reflected continued investment in our
commercial organization, included the expansion of our INGREZZA and CRENESSITY
sales teams in the first quarter of 2026 and for support of VYKAT XR following
the acquisition of Soleno, which closed in May 2026.

◦ Third-quarter 2026 includes $52 million loss from changes in fair values of
equity investments, compared with a gain of $31 million for third quarter 2025
(Non-GAAP adjustment)

• At September 30, 2026, the Company had cash, cash equivalents, and marketable
securities totaling approximately $790 million.
                                                                                
   Full Year 2026 Financial Guidance                                            
                                                                                
                                                                                
  (dollars in millions)                               Prior            Updated  
  INGREZZA Net Product Sales1               $2,825 - $2,875    $2,900 - $2,925  
  GAAP R&D2                                 $1,275 - $1,325          No Change  
  Non-GAAP R&D2, 3                          $1,140 - $1,190          No Change  
  IPR&D4                                                $23                $34  
  GAAP SG&A5                                $1,575 - $1,600    $1,540 - $1,560  
  Non-GAAP SG&A3, 5                         $1,325 - $1,350    $1,290 - $1,310  
  GAAP Amortization of Acquired                                                 
  Intangible                                      $85 - $90          No Change  
  Assets6                                                                       
                                                                                
1. INGREZZA sales guidance reflects expected net product sales of INGREZZA in
tardive dyskinesia and chorea associated with Huntington’s disease.

2. R&D guidance reflects the continued advancement of the Company’s pre-clinical
and clinical portfolio including the Phase 3 programs for osavampator in major
depressive disorder and direclidine in schizophrenia, and includes approximately
$33 million of expense for development milestones related to our in-licensed
product candidates. Development milestones are included in R&D guidance once
achieved or deemed probable to achieve.

3. Non-GAAP guidance has been adjusted to exclude estimated non-cash stock-based
compensation expense of approximately $115 million in R&D and $170 million in
SG&A, including approximately $58 million related to the acceleration of vesting
of equity awards for Soleno employees which vested in full upon the closing of
the transaction, and acquisition, integration and divestiture-related expenses
of approximately $95 million. Non-cash stock-based compensation expense for
performance-based equity awards is included in guidance once the predefined
performance-based criteria for vesting is achieved or deemed probable to
achieve.

4. IPR&D guidance represents completed collaboration and licensing arrangements.

5. SG&A guidance reflects expense for ongoing commercial initiatives, including
the recent expansion of our sales teams in Q1 2026, supporting INGREZZA growth
and the launch of CRENESSITY and VYKAT XR.

6. In connection with the acquisition of Soleno, the Company recorded
approximately $2.2 billion of intellectual property related to VYKAT XR to the
balance sheet, which will be amortized over an expected life of 16 years.

Conference Call and Webcast Today at 4:30 PM Eastern Time

Neurocrine Biosciences will hold a live conference call and webcast today at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Participants can access the
live conference call by dialing 800-347-6865 (US) or 203-518-9757
(International) using the conference ID: NBIX. The webcast and accompanying
slides can also be accessed at approximately 4:30 p.m. Eastern Time on
Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay
of the webcast will be available on the website approximately one hour after the
conclusion of the event and will be archived for approximately one month.
                                                                                
  About Neurocrine Biosciences                                                  
                                                                                
Neurocrine Biosciences is a leading biopharmaceutical company with a simple
purpose: to relieve suffering for people with great needs. We are dedicated to
discovering, developing and commercializing life-changing treatments for
patients with under-addressed neurological, psychiatric, endocrine and
immunological disorders. The company’s diverse portfolio includes FDA-approved
treatments for tardive dyskinesia, chorea associated with Huntington’s disease,
classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome,
endometriosis* and uterine fibroids*, as well as a robust pipeline including
multiple compounds in mid- to late-phase clinical development across our core
therapeutic areas. For more than three decades, we have applied our unique
insight into neuroscience and the interconnections between brain and body
systems to treat complex conditions. We relentlessly pursue medicines to ease
the burden of debilitating diseases and disorders, because you deserve brave
science. For more information, visit neurocrine.com, and follow the company on
LinkedIn, X, Facebook and YouTube. (* in collaboration with AbbVie )

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE,
INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences,
Inc. VYKAT is a registered trademark of Soleno Therapeutics, Inc.
                                                                                
   Non-GAAP Financial Measures                                                  
                                                                                
In addition to the financial results and financial guidance that are provided in
accordance with accounting principles generally accepted in the United States
(GAAP), this press release also contains the following Non-GAAP financial
measures: Non-GAAP cost of revenues, Non-GAAP R&D expense, Non-GAAP SG&A
expense, Non-GAAP other income (expense), net, Non-GAAP net income and earnings
per share. When preparing the Non-GAAP financial results and guidance, the
Company excludes certain GAAP items that management does not consider to be
normal, including recurring cash operating expenses that might not meet the
definition of unusual or non-recurring items. In particular, these Non-GAAP
financial measures exclude: non-cash stock-based compensation expense,
amortization expense related to acquired intangible assets, amortization expense
related to acquisition-date inventory fair value step-up, stock based
compensation expense related to the acceleration of vesting of equity awards for
Soleno employees, changes in fair value of equity investments, acquisition-
related transaction and integration costs, gains on sales of businesses, net of
transaction costs, other divestiture-related transaction costs, changes in
foreign currency exchange rates and certain adjustments to income tax expense.
These Non-GAAP financial measures are provided as a complement to results
provided in accordance with GAAP as management believes these Non-GAAP financial
measures are useful to investors because they help indicate underlying trends in
the Company's business, are important in comparing current results with prior
period results and provide additional information regarding the Company's
financial position. Management also uses these Non-GAAP financial measures to
establish budgets and operational goals that are communicated internally and
externally and to manage the Company's business and evaluate its performance.
The Company provides guidance regarding combined R&D and SG&A expenses on both a
GAAP and a Non-GAAP basis. A reconciliation of these GAAP financial results to
Non-GAAP financial results is included in the attached financial information.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
In addition to historical facts, this press release contains forward-looking
statements that involve a number of risks and uncertainties. These statements
include, but are not limited to, statements related to: our business strategy,
objectives, and future development plans; the benefits to be derived from our
products and product candidates; the value our products and/or our product
candidates may bring to patients; the continued success of INGREZZA;
successfully commercializing CRENESSITY and VYKAT XR; our financial and
operating performance, including our future revenues, expenses, or profits; our
full year 2026 financial guidance; our acquisition of Soleno Therapeutics,
including the prospective benefits of the acquisition, and our strategy, plans,
objectives, expectations (financial or otherwise) and intentions with respect to
our future financial results, growth potential and anticipated product portfolio
in connection with the acquisition; our collaborative partnerships; clinical and
scientific data updates for our products and product candidates, including
observations regarding clinical outcomes, safety, and tolerability; expected
future clinical and regulatory milestones; and the timing of the initiation
and/or completion of our clinical, regulatory, and other development activities
and those of our collaboration partners. Factors that could cause actual results
to differ materially from those stated or implied in the forward-looking
statements, include but are not limited to the following: risks and
uncertainties associated with Neurocrine Biosciences’ business and finances in
general; risks and uncertainties associated with the commercialization of our
products; risks related to our ability to realize the anticipated benefits of
the acquisition of Soleno Therapeutics, including the possibility that the
expected benefits from the acquisition will not be realized or will not be
realized within the expected time period and that we will not be able to
integrate Soleno Therapeutics’ business successfully or that such integration
may be more difficult, time-consuming or costly than expected, disruption from
the acquisition, making it more difficult to conduct business as usual or
maintain relationships with employees, customers, suppliers, other business
partners or governmental entities, unknown or inestimable liabilities, the risk
of litigation and/or regulatory actions related to the acquisition, and the
degree and pace of market uptake of VYKAT XR; risks related to the development
of our product candidates; risks associated with our dependence on third parties
for development, manufacturing, and commercialization activities for our
products and product candidates, and our ability to manage these third parties;
risks that the FDA or other regulatory authorities may make adverse decisions
regarding our products or product candidates; risks that development activities
may not be initiated or completed on time or at all, or may be delayed for
regulatory, manufacturing, or other reasons, may not be successful or replicate
previous clinical trial results, may fail to demonstrate that our product
candidates are safe and effective, or may not be predictive of real-world
results or of results in subsequent clinical trials; risks that the potential
benefits of the agreements with our collaboration partners may never be
realized; risks that our products, and/or our product candidates may be
precluded from commercialization by the proprietary or regulatory rights of
third parties, or have unintended side effects, adverse reactions or incidents
of misuse; risks associated with government and third-party regulatory and/or
policy efforts which may, among other things, impose sales and pharmaceutical
pricing controls on our products or limit coverage and/or reimbursement for our
products; risks associated with competition from other therapies or products,
including potential generic entrants for our products; risks associated with our
ability to manage the growth of our organization; and other risks described in
our periodic reports filed with the Securities and Exchange Commission.
Neurocrine Biosciences disclaims any obligation to update the statements
contained in this press release after the date hereof other than as required by
law.
                                      ###                                       
                                                                                
  Contact: Neurocrine Biosciences, Inc.                                         
                                                                                
Tony Jewell (Media)

858-617-7578 [email protected]

Todd Tushla (Investors)

858-617-7143

[email protected]
                                                                                
                                    TABLE 1                                     
                                                                                
                                                                                
                          NEUROCRINE BIOSCIENCES, INC.                          
                                                                                
                                                                                
                  CONDENSED CONSOLIDATED STATEMENTS OF INCOME                   
                                                                                
                (unaudited, in millions, except per share data)                 
                                                                                
            Three                              Nine                             
            Months                             Months                           
            Ended                              Ended                            
            Septem…                            Septe…                           
            30,                                30,                              
  Reven…    2026                2025           2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  produ…    $        1,119.0    $     789.9    $       2,884.3    $     2,035…  
  sales                                                                         
  Colla…                 3.7            5.0               11.9            19.4  
  reven…                                                                        
  Total              1,122.7          794.9            2,896.2          2,055…  
  reven…                                                                        
  Opera…                                                                        
  expen…                                                                        
  Cost                                                                          
  of                                                                            
  reven…                                                                        
  exclu…                                                                        
  amort…                26.6           13.0               63.5            31.5  
  of                                                                            
  acqui…                                                                        
  intan…                                                                        
  assets                                                                        
  Resea…                                                                        
  and                  351.8          250.0              974.7           757.5  
  devel…                                                                        
  Acqui…                                                                        
  in-pr…                                                                        
  resea…                11.7            0.3               34.4             0.4  
  and                                                                           
  devel…                                                                        
  Selli…                                                                        
  gener…               366.3          291.6            1,124.5           854.4  
  and                                                                           
  admin…                                                                        
  Amort…                                                                        
  of                                                                            
  acqui…                35.0            1.0               51.5             3.0  
  intan…                                                                        
  assets                                                                        
  Gain                                                                          
  on                                                                            
  sale                                                                          
  of                       —              —              -28.6               —  
  busin…                                                                        
  net of                                                                        
  trans…                                                                        
  costs                                                                         
  Total                                                                         
  opera…               791.4          555.9            2,220.0          1,646…  
  expen…                                                                        
  Opera…               331.3          239.0              676.2           408.2  
  income                                                                        
  Other                                                                         
  (expe…                                                                        
  income                                                                        
  :                                                                             
  Inter…                -0.3              —               -3.2               —  
  expen…                                                                        
  Unrea…                                                                        
  (loss)                                                                        
  gain                 -52.3           30.6              -25.8            -6.7  
  on                                                                            
  equity                                                                        
  inves…                                                                        
  Inves…                                                                        
  income                                                                        
  and                    5.0           22.2               45.5            64.5  
  other,                                                                        
  net                                                                           
  Total                                                                         
  other                                                                         
  (expe…               -47.6           52.8               16.5            57.8  
  incom…                                                                        
  net                                                                           
  Income                                                                        
  before                                                                        
  provi…               283.7          291.8              692.7           466.0  
  for                                                                           
  income                                                                        
  taxes                                                                         
  Provi…                                                                        
  for                   77.2           82.3              143.9           141.1  
  income                                                                        
  taxes                                                                         
  Net       $          206.5    $     209.5    $         548.8    $      324.9  
  income                                                                        
  Earni…                                                                        
  per       $           2.03    $      2.11    $          5.43    $       3.27  
  share,                                                                        
  basic                                                                         
  Earni…                                                                        
  per       $           1.96    $      2.04    $          5.26    $       3.19  
  share,                                                                        
  dilut…                                                                        
  Weigh…                                                                        
  avera…                                                                        
  common               101.6           99.4              101.0            99.3  
  shares                                                                        
  outst…                                                                        
  basic                                                                         
  Weigh…                                                                        
  avera…                                                                        
  common               105.2          102.5              104.3           102.0  
  shares                                                                        
  outst…                                                                        
  dilut…                                                                        
                                                                                
                                                                                
                                    TABLE 2                                     
                                                                                
                                                                                
                          NEUROCRINE BIOSCIENCES, INC.                          
                                                                                
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
                            (unaudited, in millions)                            
                                                                                
                                              September 30,       December 31,  
                                                       2026               2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash, cash equivalents, and                                                   
  marketable                               $          737.9    $       1,480.4  
  securities                                                                    
  Accounts receivable                                 957.3              686.8  
  Inventory                                            66.1               69.0  
  Other current assets                                246.9              286.5  
  Total current assets                              2,008.2            2,522.7  
  Noncurrent inventory                                177.7                  —  
  Noncurrent marketable securities                     51.8            1,063.0  
  Right-of-use assets                                 437.2              455.4  
  Equity investments                                   95.0              120.8  
  Property and equipment, net                          92.2               89.8  
  Intangible assets, net                            2,191.0                4.7  
  Goodwill                                            500.6                6.1  
  Deferred tax assets                                  11.8              320.3  
  Other noncurrent assets                              61.9               48.7  
  Total assets                             $        5,627.4    $       4,631.5  
  Total current liabilities                           984.6              743.4  
  Deferred tax liabilities                            105.0                  —  
  Noncurrent operating lease                          392.3              415.3  
  liabilities                                                                   
  Other noncurrent liabilities                        266.8              219.7  
  Stockholders’ equity                              3,878.7            3,253.1  
  Total liabilities and stockholders’      $        5,627.4    $       4,631.5  
  equity                                                                        
                                                                                
                                                                                
                                    TABLE 3                                     
                                                                                
                                                                                
                          NEUROCRINE BIOSCIENCES, INC.                          
                                                                                
                                                                                
              RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS              
                                                                                
                (unaudited, in millions, except per share data)                 
                                                                                
                        Three                              Nine                 
                       Months                            Months                 
                        Ended                             Ended                 
                    September                         September                 
              2026        30,    2025           2026        30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP net    $         206.5    $     209.5    $         548.8    $     324.9  
  income1                                                                       
  Adjustm…                                                                      
  Stock-b…                                                                      
  compens…               54.3           53.7              176.5          159.3  
  expense                                                                       
  Acceler…                                                                      
  of                                                                            
  stock-b…                                                                      
  compens…                  —              —               60.1              —  
  expense                                                                       
  and                                                                           
  related                                                                       
  taxes2                                                                        
  Acquisi…                                                                      
  employee                                                                      
  compens…               16.7              —               38.6              —  
  and                                                                           
  severan…                                                                      
  costs                                                                         
  Amortiz…                                                                      
  of                                                                            
  invento…                6.3              —                9.3              —  
  fair                                                                          
  value                                                                         
  step-up3                                                                      
  Amortiz…                                                                      
  of                                                                            
  acquired               35.0            1.0               51.5            3.0  
  intangi…                                                                      
  assets4                                                                       
  Acquisi…                                                                      
  transac…                                                                      
  and                     1.9              —               50.6              —  
  integra…                                                                      
  costs                                                                         
  Gain on                                                                       
  sale of                                                                       
  busines…                  —              —              -28.6              —  
  net of                                                                        
  transac…                                                                      
  costs5                                                                        
  Changes                                                                       
  in fair                                                                       
  values                 52.3          -30.6               25.8            6.7  
  of                                                                            
  equity                                                                        
  investm…                                                                      
  Other7                  1.9            0.8                3.2            3.1  
  Income                                                                        
  tax                                                                           
  effect                                                                        
  related               -28.2          -12.3              -91.9          -37.1  
  to                                                                            
  reconci…                                                                      
  items8                                                                        
  Non-GAAP                                                                      
  net         $         346.7    $     222.1    $         843.9    $     459.9  
  income1                                                                       
  Diluted                                                                       
  earnings                                                                      
  per                                                                           
  share:                                                                        
  GAAP        $          1.96    $      2.04    $          5.26    $      3.19  
  Non-GAAP    $          3.29    $      2.17    $          8.09    $      4.51  
                                                                                
                                                                                
                              TABLE 3 (CONTINUED)                               
                                                                                
                                                                                
                          NEUROCRINE BIOSCIENCES, INC.                          
                                                                                
                                                                                
              RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS              
                                                                                
                            (unaudited, in millions)                            
                                                                                
             Three                            Nine                              
             Months                           Months                            
             Ended                            Ended                             
             Septem…                          Septemb…                          
  Cost of    30,                              30,                               
  Revenu…    2026              2025           2026                 2025         
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  cost of    $         26.6    $      13.0    $            63.5    $      31.5  
  revenu…                                                                       
  Adjust…                                                                       
  Accele…                                                                       
  of                                                                            
  stock-…                                                                       
  compen…                 —              —                  1.8              —  
  expense                                                                       
  and                                                                           
  related                                                                       
  taxes2                                                                        
  Acquis…                                                                       
  employ…                                                                       
  compen…                 —              —                  0.2              —  
  and                                                                           
  severa…                                                                       
  costs                                                                         
  Amorti…                                                                       
  of                                                                            
  invent…               6.3              —                  9.3              —  
  fair                                                                          
  value                                                                         
  step-u…                                                                       
  Non-GA…                                                                       
  cost of    $         20.3    $      13.0    $            52.2    $      31.5  
  revenu…                                                                       
  Resear…                                                                       
  and                                                                           
  Develo…                                                                       
  GAAP       $        351.8    $     250.0    $           974.7    $     757.5  
  R&D                                                                           
  Adjust…                                                                       
  Stock-…                                                                       
  compen…              24.7           22.0                 76.4           66.6  
  expense                                                                       
  Accele…                                                                       
  of                                                                            
  stock-…                                                                       
  compen…                 —              —                 18.1              —  
  expense                                                                       
  and                                                                           
  related                                                                       
  taxes2                                                                        
  Acquis…                                                                       
  employ…                                                                       
  compen…               8.9              —                 13.9              —  
  and                                                                           
  severa…                                                                       
  costs                                                                         
  Other7                1.2              —                  1.2              —  
  Non-GA…    $        317.0    $     228.0    $           865.1    $     690.9  
  R&D                                                                           
  Sellin…                                                                       
  Genera…                                                                       
  and                                                                           
  Admini…                                                                       
  GAAP       $        366.3    $     291.6    $         1,124.5    $     854.4  
  SG&A                                                                          
  Adjust…                                                                       
  Stock-…                                                                       
  compen…              29.6           31.7                100.1           92.7  
  expense                                                                       
  Accele…                                                                       
  of                                                                            
  stock-…                                                                       
  compen…                 —              —                 40.2              —  
  expense                                                                       
  and                                                                           
  related                                                                       
  taxes2                                                                        
  Acquis…                                                                       
  employ…                                                                       
  compen…               7.8              —                 24.5              —  
  and                                                                           
  severa…                                                                       
  costs                                                                         
  Acquis…                                                                       
  transa…                                                                       
  and                   1.9              —                 45.5              —  
  integr…                                                                       
  costs                                                                         
  Other7                0.4            0.5                  1.5            2.4  
  Non-GA…    $        326.6    $     259.4    $           912.7    $     759.3  
  SG&A                                                                          
  Amorti…                                                                       
  of                                                                            
  Acquir…                                                                       
  Intang…                                                                       
  Assets:                                                                       
  GAAP                                                                          
  amorti…                                                                       
  of         $         35.0    $       1.0    $            51.5    $       3.0  
  acquir…                                                                       
  intang…                                                                       
  assets                                                                        
  Adjust…                                                                       
  Amorti…                                                                       
  of                                                                            
  acquir…              35.0            1.0                 51.5            3.0  
  intang…                                                                       
  assets4                                                                       
  Non-GA…                                                                       
  amorti…                                                                       
  of         $            —    $         —    $               —    $         —  
  acquir…                                                                       
  intang…                                                                       
  assets                                                                        
  Gain on                                                                       
  Sale of                                                                       
  Busine…                                                                       
  Net of                                                                        
  Transa…                                                                       
  Costs:                                                                        
                                                                                
  GAAP                                                                          
  gain on                                                                       
  sale of                                                                       
  busine…    $            —    $         —    $           -28.6    $         —  
  net of                                                                        
  transa…                                                                       
  costs                                                                         
  Adjust…                                                                       
  Gain on                                                                       
  sale of                                                                       
  busine…                 —              —                -28.6              —  
  net of                                                                        
  transa…                                                                       
  costs5                                                                        
  Non-GA…                                                                       
  gain on                                                                       
  sale of                                                                       
  busine…    $            —    $         —    $               —    $         —  
  net                                                                           
  of                                                                            
  transa…                                                                       
  costs                                                                         
  Other                                                                         
  Income                                                                        
  (Expen…                                                                       
  GAAP                                                                          
  other                                                                         
  (expen…    $        -47.6    $      52.8    $            16.5    $      57.8  
  income,                                                                       
  net                                                                           
  Adjust…                                                                       
  Changes                                                                       
  in fair                                                                       
  values               52.3          -30.6                 25.8            6.7  
  of                                                                            
  equity                                                                        
  invest…                                                                       
  Acquis…                                                                       
  transa…                                                                       
  and                     —              —                  5.1              —  
  integr…                                                                       
  costs                                                                         
  Other7                0.3            0.3                  0.5            0.7  
  Non-GA…                                                                       
  other      $          5.0    $      22.5    $            47.9    $      65.2  
  income,                                                                       
  net                                                                           
                                                                                
                                                                                
                              TABLE 3 (CONTINUED)                               
                                                                                
                                                                                
                          NEUROCRINE BIOSCIENCES, INC.                          
                                                                                
                                                                                
              RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS              
                                                                                
                (unaudited, in millions, except per share data)                 
1. Includes the following expenses:
                                                                                
                          Three                             Nine                
                         Months                           Months                
                          Ended                            Ended                
                      September                        September                
               2026         30,    2025         2026         30,    2025        
 ────────────────────────────────────────────────────────────────────────────── 
  Mileston…    $           10.0    $     1.0    $           32.9    $     61.5  
  (R&D)                                                                         
  Acquired                                                                      
  in-proce…                                                                     
  research     $           11.7    $     0.3    $           34.4    $      0.4  
  and                                                                           
  developm…                                                                     
  (IPR&D)                                                                       
                                                                                
2. Relates to the acceleration of vesting of equity awards for Soleno employees
which vested in full upon the closing of the transaction.

3. Relates to amortization expense associated with recording approximately $168
million of VYKAT XR inventory fair value step-up.

4. Primarily relates to amortization of acquired intangible assets associated
with the recording of approximately $2.2 billion of intellectual property
related to VYKAT XR, which will be amortized over 16 years.

5. Reflects a pre-tax gain, net of transaction costs, recognized on the sale of
Neurocrine Group Limited in January 2026.

6. Reflects periodic fluctuations in the fair values of equity investments.

7. Reflects non-cash interest expense related to the Company's credit facility,
legacy campus facility costs, net of sublease income, and other immaterial costs
that management does not consider indicative of the Company's ongoing operating
performance.

8. Estimated income tax effect of Non-GAAP reconciling items are calculated
using applicable statutory tax rates, taking into consideration any valuation
allowance. In addition, Non-GAAP tax expense may also be affected by certain
non-recurring, non-operating, or discrete tax items.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.